Graft vs. host disease (GVHD) is a serious condition that can occur after a stem cell transplant from a donor, where the ...

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light.

A GVHD rash usually resembles a sunburn and can ... If your skin is resistant to steroids, your transplant team may suggest extracorporeal photopheresis, a form of light therapy that involves ...

A panelist discusses how the treatment landscape for chronic graft-vs-host disease (cGVHD) has evolved significantly in ...

This review has aimed to highlight the successful treatment of steroid-refractory and steroid-dependent, acute and chronic GvHD with ECP. This novel treatment appears to offer selective ...

The ‘rolling’ biologics license application (BLA) for remestemcel-L in children with steroid-refractory acute GVHD – a life-threatening complication that can arise in blood cancer patients ...

Ruxolitinib is recommended, within its marketing authorisation, as an option for treating acute graft versus host disease (GvHD) that has an inadequate response to corticosteroids in people 12 years ...